Among 12 clarithromycin-resistant Helicobacter pylori strains isolated in Guri, Korea, 8 showed an adenine to guanine mutation at position 2143 (formerly A2144G or E. coli 2059) in the 23S rRNA gene by the PCR-restriction fragment length polymorphism (RFLP) method. The remaining 4 strains, digested by neither BsaI nor BbsI, showed a thymine to cytosine mutation at position 2182 (T2182C) by direct sequencing of the PCR products. The T2182C mutants showed a tendency of higher levels of minimum inhibitory concentration to clarithromycin than the A2143G mutants. In conclusion, either the A2143G or the T2182C mutation was present in 100% of clarithromycin-resistant H. pylori isolates examined. The PCR-RFLP technique with restriction enzymes BbsI and BsaI was a rapid and relatively simple method to detect the clarithromycin resistance. But undigested isolates were quite frequent among our isolates (33.3%), the PCR-RFLP method with restriction enzymes BbsI and BsaI should not be used alone, and development of other rapid detection method for clarithromycin resistance is mandatory.
INTRODUCTION
The prevalence rate of antimicrobial resistance to Helicobacter pylori varies with geographical regions, but almost all H. pylori strains are susceptible to amoxicillin, while 1 to 13% of strains are resistant to clarithromycin and 20 to 70% of strains are resistant to metronidazole (1) (2) (3) . In Korea, the prevalence rate of metronidazole resistance approaches 50%, but the clarithromycin resistance rate was reported to be below 5%, however, has begun to increase recently (4, 5) . Therefore the most widely used primary regimen for H. pylori eradication in Korea is the triple therapy with clarithromycin, amoxicillin, and a proton-pump inhibitor.
The impact of antimicrobial resistance on the eradication of H. pylori has been reviewed by several investigators (6) (7) (8) . The cure rate with metronidazole-based combination regimens in patients with metronidazole-resistant strains was decreased by 20 to 50%, compared to patients harboring metronidazole-susceptible strains (6, 7) . In case of clarithromycin resistance, the efficacy of clarithromycin-based triple therapy was also decreased by more than 50% (8) . Therefore, in Korea or elsewhere, the clarithromycin resistance is a prime concern for clinicians who treat the ulcer patients infected with H. pylori. Clinical microbiology laboratory of Hanyang University Guri Hospital routinely performs the antimicrobial susceptibility testing of H. pylori for clarithromycin since 1996 by the modified broth microdilution method (4) . As culture and susceptibility testing of H. pylori are time-and labor-demanding procedure, we have tried to develop rapid detection methods for clarithromycin resistance by molecular methods.
Versalovic et al. showed that point mutations in two positions (A to G at 2142, 2143) in 23S rRNA domain V were associated with macrolide resistance (9) . With appropriate restriction enzymes (BbsI and BsaI) and the PCR-restriction fragment length polymorphism (RFLP) technique, Occhialini et al. developed a relatively simple method detecting these mutations (10) . The aim of this study was to detect the point mutations in the peptidyltransferase region of 23S rRNA and to evaluate the molecular method for the detection of clarithromycin-resistant H. pylori isolates from Guri, Korea.
MATERIALS AND METHODS

Isolation and identification
H. pylori were isolated from gastric biopsy specimens from patients diagnosed as peptic ulcer or gastric carcinoma from 1996 through 2001 in Hanyang University Guri Hospital. Culture was performed on brain heart infusion (BHI) agar containing 5% sheep blood and the inoculated plates were incubated at 37℃ for 3 to 6 days under microaerobic conditions generated by Campy-Pak Plus (BBL Microbiology System, Cockeysville, Md., U.S.A.). Identification was based on the Gram stain morphology and the presence of oxidase, catalase, and urease activities.
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) were determined by the modified broth microdilution method as described by Kim et al. (4) . Isolates were subcultured for 72 hr and saline suspensions of No. 2 McFarland standard were prepared. Serial dilutions of clarithromycin at concentrations ranging from 0.125 to 64 g/mL were prepared in distilled water. A suspension of each isolate was inoculated into the clarithromycin-containing 96-well microplate. Plates were incubated at 37℃ for 3 days under microaerobic condition, and the MIC was recorded as the lowest concentration of the antibiotic inhibiting the visible growth of H. pylori. Resistance was defined as the clarithromycin MIC being ≥1 g/mL (11) . The amplified products (fragment A amplicon) were digested with BbsI and BsaI (New England Biolabs, Inc., Beverly, Mass., U.S.A.) as described by Occhialini et al. (1997) , which allow discrimination between the wild type, the A2142G mutant (BbsI restriction site), and the A2143G mutant (BsaI restriction site). Ten microliters of the amplicon A (425 bp) was incubated for 24 hr at 56℃ for BsaI and at 37℃ for BbsI in order to detect the restriction site occurring when the mutation was A to G at 2143 (formerly 2144) or at 2142 (formerly 2143), respectively. The restriction products were analyzed by electrophoresis on 2% agarose gel.
Detection of mutations
PCR products were purified and concentrated with an agarose gel DNA extraction kit (Roche, Germany). The same primers for PCR amplification were used for sequencing. Sequencing was performed on the two strands of each amplicon with an automated DNA sequencer (the ABI PRISM 377XL) and with the sequencing kit (Perkin-Elmer).
RESULTS
Among the 271 clinical isolates of H. pylori from 1996 through 2001, 18 isolates (6.6%) showed clarithromycin resistance. MIC distribution of the 18 clarithromycin-resistant strains varied from 1 g/mL in 16.7%, 2 g/mL in 5.6%, 4 g/mL in 11.1%, 8 g/mL in 16.7%, 16 g/mL in 5.6%, 32 g/mL in 5.6%, and ≥64 g/mL in 38.9%. Among the 12 resistant isolates that were available for the PCR, BsaI restriction enzyme cut the PCR-products of 8 strains to 304 bp and 101 bp bands (Fig. 1) , indicating that the 8 strains had an A to G mutation at position 2143 (A2143G). Neither BbsI nor BsaI digested the PCR products of remaining the 4 strains. On sequencing the PCR products of these 4 strains, all four isolates showed a point mutation of T to C at position 2182 (T2182C). MICs of the A2143G mutant strains were relatively low from 1 to 8 g/mL, except two isolates (both, ≥64 g/mL). In contrast, MICs of the T2182C mutants were relatively high from 16 g/mL to ≥64 g/mL ( Table 1) . PCR-RFLP analysis of 14 clarithromycin-susceptible (< 0.5 g/mL) strains of H. pylori showed neither A2142G nor A2143G mutations. The PCR products of the four isolates among the 14 undigested clarithromycin-susceptible H. pylori were sequenced, but disclosed no mutation sites.
DISCUSSION
The clarithromycin resistance is a prime concern for physicians who are using clarithromycin-based triple therapy as a primary regimen for ulcer patients infected with H. pylori. Physicians ask for an antimicrobial susceptibility testing for clarithromycin, but the culture of this fastidious bacterium takes time and effort, and moreover, antimicrobial susceptibility testing is not practically possible for most clinical microbiology laboratories due to its technical difficulty, cost, and labor. One solution to this problem is offered by the techniques based on PCR.
Resistance to macrolides is caused by a decrease in binding of macrolides to the ribosome, which is associated with Erm methylation of A2058 (Escherichia coli numbering) or mutation at A2058 of 23S rRNA (12, 13) . In 1996, Versalovic et al. first reported the association of clarithromycin resistance of H. pylori with a single point mutation within the domain V of 23S r RNA (9). They identified A to G transition mutations at positions cognate with Escherichia coli 23S rRNA positions 2058 and 2059, and later named them positions 2143 and 2144 according to the entire H. pylori 23S rRNA sequence by GenBank no. U27270 (14) . Taylor et al. determined the DNA sequences of the two copies of the 23S rRNA gene from H. pylori UA802 and compared the sequences from clarithromycin-resistant strains. They defined the 5′end of the H. pylori 23S rRNA as position 373 A, and therefore, they proposed that the positions associated with clarithromycin resistance within the H. pylori 23S rRNA be defined as nucleotides 2142 and 2143. Most investigators choose to numerate the residues 2142 and 2143 according to the definition of the structure of the 23S rRNA gene in H. pylori published by Taylor et al. (15) .
The prevalence of mutant strains among the clarithromycin-resistant H. pylori varies in different parts of the world. Studies from U.S.A. revealed 48% to 53% of A2142G mutation, 39% to 45% of A2143G mutation, and 0% to 7% of A2142C mutation (14, 16) . The prevalence of the A2142G mutation in Europe was reported as 23% to 33%, A2143G mutation as 44% to 67%, and A2142C mutation as 2% to 10% (17, 18) . However, studies from Japan (19, 20) showed that more than 90% of the mutant strains had the A2143G mutation and the A2142C mutation was not detected. Although the number of the strains was small, a study from China also showed 100% of A2143G mutation in clarithromycin-resistant H. pylori (21) .
The incidence of clarithromycin resistance in H. pylori isolated in Korea has been reported below 10%, but the preva- lence of resistant strains is increasing due to the widespread use of macrolides as a primary regimen for H. pylori infections or for the treatment of respiratory tract infection in pediatric patients (4, 5) . Therefore, characterization of the resistance mechanism in each country will facilitate the development of a rapid detection method, the choice of appropriate treatment regimens, and ultimately, the control of the infection.
In our study, all the 12 clarithromycin-resistant strains isolated at Hanyang University Guri Hospital had point mutations at the 23S rRNA gene of H. pylori. The most prevalent mutation was A2143G (66.7%) and the A2142G mutants were not identified. Our results are different from those of Europe or U.S.A. (14, (16) (17) (18) , but similar with those of Japan and China where the major type of mutation was reported as A2143G (19) (20) (21) . One study from Korea revealed that A2142G mutation was observed in 87.0%, and A2143G mutation in 13.0% (22) . But in the results of Song et al. (23) , three of four clarithromycin-resistant isolates showed A2143G mutation and one isolate showed C2215T mutation. In H. pylori, seven different point mutations (A2142G or C, A2143G or C, A2115G, G2141A, and A2142T) in the 23S rRNA gene have been found to be associated with the resistance to clarithromycin (18, 24) .
Most notable finding of our study is the T2182 to C mutation that has not been reported in H. pylori isolated in Korea. The A to G transition mutation is presently the most frequent substitution and has genetic stability and growth advantage compared to the wild-type strain or to strains with any of other bases at these positions (17, 25) . Also, the A2142G gives the highest level of resistance to clarithromycin, but the A2143G mutants have lower levels of clarithromycin resistance than the A2142G mutants (14) . Our results also showed that the A2143G mutation was related to the low levels of clarithromycin MICs. Although the underlying mechanism for this phenomenon has not been known, the T2182C mutation seems to be associated with high levels of clarithromycin resistance in H. pylori isolated in Guri, Korea.
In conclusion, we found a rare mutation site (T2182C) from the clarithromycin-resistant H. pylori strains isolated in Guri, Korea. To prove the association of T2182C mutation with the clarithromycin resistance, further study will be needed. The A2143G mutation was quite frequently observed (8/12) and the T2182C mutation (4/12) was also observed. The A2142G mutation was not found in this study. Because the T2182C mutation was quite frequent among our isolates, the PCR-RFLP method with restriction enzymes BbsI and BsaI should not be used alone, and development of other rapid detection method for clarithromycin resistance is mandatory.
